Proportion of Patients With Clinical Symptom Requiring Hospitalization, Oxygen Therapy, or Experiencing Mortality Due to SARS-CoV-2 Infection (Part 1);Proportion of Patients With Clinical Symptom Requiring Hospitalization, Oxygen Therapy, or Experiencing Mortality Due to SARS-CoV-2 Infection up to Day 28 in High-risk Patients (Part 2);Proportion of Patients With Negative Conversion in Nasopharyngeal Swab Specimen Based on RT-qPCR at Each Visit (Part 1);Time to Clinical Recovery (Part 1);Time to Negative Conversion in Nasopharyngeal Swab Specimen (Part 1)

Proportion of Patients With Clinical Symptom Requiring Hospitalization, Oxygen Therapy, or Experiencing Mortality Due to SARS-CoV-2 Infection (Part 1);Proportion of Patients With Clinical Symptom Requiring Hospitalization, Oxygen Therapy, or Experiencing Mortality Due to SARS-CoV-2 Infection up to Day 28 in High-risk Patients (Part 2);Proportion of Patients With Negative Conversion in Nasopharyngeal Swab Specimen Based on RT-qPCR at Each Visit (Part 1);Time to Clinical Recovery (Part 1);Time to Negative Conversion in Nasopharyngeal Swab Specimen (Part 1)

Proportion of patients with clinical symptom requiring hospitalization, oxygen therapy, or experiencing mortality due to SARS-CoV-2 infection for Part 1 (Phase II);Proportion of patients with clinical symptom requiring hospitalization, oxygen therapy, or experiencing mortality due to SARS-CoV-2 infection in high-risk patients for Part 2 (Phase III);Proportion of patients with negative conversion in nasopharyngeal swab specimen based on RT-qPCR or cell culture at each visit for Part 1 (Phase II);Time to clinical recovery for Part 1 (Phase II);Time to negative conversion in nasopharyngeal swab specimen based on RT-qPCR or cell culture at each visit for Part 1 (Phase II)

Proportion of patients with clinical symptom requiring hospitalization, oxygen therapy, or experiencing mortality due to SARS-CoV-2 infection for Part 1 (Phase II);Proportion of patients with clinical symptom requiring hospitalization, oxygen therapy, or experiencing mortality due to SARS-CoV-2 infection in high-risk patients for Part 2 (Phase III);Proportion of patients with negative conversion in nasopharyngeal swab specimen based on RT-qPCR or cell culture at each visit for Part 1 (Phase II);Time to clinical recovery for Part 1 (Phase II);Time to negative conversion in nasopharyngeal swab specimen based on RT-qPCR or cell culture at each visit for Part 1 (Phase II)

To evaluate the therapeutic efficacy CT-P59 for Part 1 (Phase II);To evaluate the therapeutic efficacy CT-P59 for Part 2 (Phase III);To evaluate the therapeutic efficacy CT-P59 for Part 1 (Phase II);To evaluate the therapeutic efficacy CT-P59 for Part 1 (Phase II);To evaluate the therapeutic efficacy CT-P59 for Part 1 (Phase II)

To evaluate the therapeutic efficacy CT-P59 for Part 1 (Phase II);To evaluate the therapeutic efficacy CT-P59 for Part 2 (Phase III);To evaluate the therapeutic efficacy CT-P59 for Part 1 (Phase II);To evaluate the therapeutic efficacy CT-P59 for Part 1 (Phase II);To evaluate the therapeutic efficacy CT-P59 for Part 1 (Phase II)